Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
British Journal of Cancer advance online publication, January 19 2017. doi:10.1038/bjc.2016.419
Authors: Adil Daud, Harriet M Kluger, Razelle Kurzrock, Frauke Schimmoller, Aaron L Weitzman, Thomas A Samuel, Ali H Moussa, Michael S Gordon & Geoffrey I Shapiro
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2k6xivT
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου